Alopecia Areata Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech

Posted on
by

Alopecia Areata Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech
The Alopecia Areata Market size was valued approximately USD 170 million in 2022 and the report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the 7MM.

The Alopecia Areata market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.  

 

DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Alopecia Areata market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Alopecia Areata market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alopecia Areata Market Insights

 

Some of the key facts of the Alopecia Areata Market Report: 

  • The Alopecia Areata market size was valued approximately USD 170 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, there were approximately 704,000 existing cases of alopecia areata in the United States, with projections indicating an expected rise by 2032.
  • Alopecia areata is classified into mild, moderate, and severe categories based on its severity. In the US, there were approximately 99,000 instances of mild alopecia areata, around 408,000 cases of moderate alopecia areata, and roughly 197,000 instances of severe alopecia areata in 2022.
  • As per the National Institute for Health and Care Excellence (NICE), alopecia areata is believed to impact 15 individuals per 10,000 in the UK. This condition can manifest at any age, with both males and females being equally susceptible.
  • Key Alopecia Areata Companies: Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others
  • Key Alopecia Areata Therapies: PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others
  • The Alopecia Areata epidemiology based on gender analyzed that females and males are equally affected by Alopecia Areata
  • The Alopecia Areata epidemiology based on gender analyzed that Alopecia Areata affects both males and females equally

 

Alopecia Areata Overview

Alopecia areata is an autoimmune disorder characterized by sudden hair loss that results in bald patches on the scalp or other areas of the body. It occurs when the body’s immune system mistakenly attacks hair follicles, leading to hair loss. The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune factors.

 

Get a Free sample for the Alopecia Areata Market Report:

https://www.delveinsight.com/report-store/alopecia-areata-market

 

Alopecia Areata Market  

The dynamics of the Alopecia Areata market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Alopecia Areata Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Alopecia Areata Epidemiology Segmentation:

The Alopecia Areata market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Alopecia Areata
  • Prevalent Cases of Alopecia Areata by severity
  • Gender-specific Prevalence of Alopecia Areata
  • Diagnosed Cases of Episodic and Chronic Alopecia Areata

 

Download the report to understand which factors are driving Alopecia Areata epidemiology trends @ Alopecia Areata Epidemiological Insights

 

Alopecia Areata Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched during the study period. The analysis covers Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alopecia Areata Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Alopecia Areata Therapies and Key Companies

  • PF-06651600: Pfizer
  • ADX-914: Q32 Bio Inc.
  • Upadacitinib: AbbVie
  • Daxdilimab: Amgen
  • CTP-543: Concert Pharmaceuticals
  • Deucravacitinib: Bristol-Myers Squibb
  • SHR0302: Reistone Biopharma
  • IMG-007: Inmagene LLC
  • Jaktinib: Suzhou Zelgen Biopharma
  • Rezpegaldesleukin: Nektar Therapeutics
  • Rosnilimab: AnaptysBio, Inc.
  • LEO 124249: LEO Pharma
  • Baricitinib: Eli Lilly and Company

 

To know more about Alopecia Areata treatment, visit @ Alopecia Areata Medications

 

Alopecia Areata Market Strengths

  • The major strength of the Alopecia areata market is its robust pipeline with the emergence of several therapies
  • Increasing awareness and development to understand the diversity of the disease might improve the diagnosis of Alopecia areata, thereby resulting in a lucrative market opportunity

 

Alopecia Areata Market Opportunities

  • Several organizations are actively working to provide information and awareness of such rare and devastating disorder
  • The current treatment options only focus on palliative treatment rather than cure, which opens a platform of new therapies to boost the market of Alopecia areata

 

Scope of the Alopecia Areata Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Alopecia Areata Companies: Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others
  • Key Alopecia Areata Therapies: PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others
  • Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
  • Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Alopecia Areata Unmet Needs, KOL’s views, Analyst’s views, Alopecia Areata Market Access and Reimbursement 

 

Discover more about therapies set to grab major Alopecia Areata market share @ Alopecia Areata market forecast

 

Table of Contents 

1. Alopecia Areata Market Report Introduction

2. Executive Summary for Alopecia Areata

3. SWOT analysis of Alopecia Areata

4. Alopecia Areata Patient Share (%) Overview at a Glance

5. Alopecia Areata Market Overview at a Glance

6. Alopecia Areata Disease Background and Overview

7. Alopecia Areata Epidemiology and Patient Population

8. Country-Specific Patient Population of Alopecia Areata 

9. Alopecia Areata Current Treatment and Medical Practices

10. Alopecia Areata Unmet Needs

11. Alopecia Areata Emerging Therapies

12. Alopecia Areata Market Outlook

13. Country-Wise Alopecia Areata Market Analysis (2019–2032)

14. Alopecia Areata Market Access and Reimbursement of Therapies

15. Alopecia Areata Market Drivers

16. Alopecia Areata Market Barriers

17.  Alopecia Areata Appendix

18. Alopecia Areata Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/